{"brief_title": "A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients", "brief_summary": "This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant recipients. The anticipated time on study treatment is 3-12 months and the target sample size is less than 100 individuals.", "condition": "Cytomegalovirus Infections", "intervention_type": "Drug", "intervention_name": "valganciclovir [Valcyte]", "description": "po daily (dose based on body surface area and CrCL)", "arm_group_label": "Valganciclovir Age Group >= 12 Years", "criteria": "Inclusion Criteria: - patients between 3 months and 16 years of age; - first solid organ transplant (eg, kidney, liver, heart); - able to tolerate oral medication; - females of childbearing potential must agree to utilize an effective method of contraception throughout the study and for 90 days following discontinuation of study drug; - patients at risk of developing CMV disease (all transplant recipients other than those who are D-R- for CMV). Exclusion Criteria: - patients who have previously participated in this study; - patients who are participating in another clinical trial (except with the approval of the Sponsor); - severe, uncontrolled diarrhea (more than 5 watery stools per day); - pregnant or lactating females.", "gender": "All", "minimum_age": "3 Months", "maximum_age": "16 Years", "healthy_volunteers": "No", "id": "NCT00090766.xml"}